AvalehtATHA • NASDAQ
add
Athira Pharma Inc
Viimane sulgemishind
0,59 $
Tänane vahemik
0,56 $ - 0,60 $
Aasta vahemik
0,41 $ - 4,30 $
Turuväärtus
21,74 mln USD
Keskmine maht
305,48 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 25,49 mln | −27,25% |
Puhastulu | −28,74 mln | 12,83% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | — | — |
EBITDA | −25,25 mln | 27,44% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 68,86 mln | −60,19% |
Kogu vara | 86,25 mln | −53,30% |
Kõik kohustused | 28,66 mln | −4,25% |
Kogu omakapital | 57,58 mln | — |
Emiteeritud aktsiate arv | 38,67 mln | — |
Hinna ja väärtuse suhe P/B | 0,40 | — |
Varade tasuvus | −64,54% | — |
Kapitali tasuvus | −88,74% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −28,74 mln | 12,83% |
Põhitegevuse rahakäive | −23,02 mln | 4,01% |
Investeeringute raha | 18,04 mln | −12,81% |
Finantseerimise raha | 12,00 tuh | — |
Raha ja raha ekvivalentide muutus | −4,97 mln | −50,94% |
Tasuta rahavoog | −10,13 mln | 13,86% |
Teave
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Asutatud
2011
Veebisait
Töötajate arv
66
